Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE Amex:SNT) today announced that the Company will be presenting at the 6 th Annual Rodman & Renshaw Global Healthcare Conference being held at the Grosvenor House Hotel in London, England from May 16 th – 18 th, 2010. Harlan Waksal, M.D., Senesco’s Executive Chairman, will deliver the Company’s corporate presentation on Monday, May 17 th, at 11:30 AM Greenwich Mean Time (6:30 AM Eastern Daylight Time.) Dr. Waksal will be available for one-on-one meetings with investors participating in the Rodman & Renshaw Global Healthcare Conference. For those who would like to schedule an appointment with Senesco management, please contact Anne Marie Fields, Lippert/Heilshorn & Associates, Inc., at 212-838-3777 or at email@example.com or contact your Rodman & Renshaw representative. The presentation will be webcast live at http://wsw.com/webcast/rrshq17/snt and at the Investor Relations section of the Company’s website at www.senesco.com where it will also be archived for 90 days. About Senesco Technologies, Inc. Senesco Technologies, Inc. is a U.S. biotechnology company, headquartered in New Brunswick, NJ. Senesco has initiated preclinical research to trigger or delay cell death in mammals (apoptosis) to determine if the technology is applicable in human medicine. Accelerating apoptosis may have applications to development of cancer treatments. Delaying apoptosis may have applications to certain diseases inflammatory and ischemic diseases. Senesco takes its name from the scientific term for the aging of plant cells: senescence. Delaying cell breakdown in plants extends freshness after harvesting, while increasing crop yields, plant size and resistance to environmental stress. The Company believes that its technology can be used to develop superior strains of crops without any modification other than delaying natural plant senescence. Senesco has partnered with leading-edge companies engaged in agricultural biotechnology and earns research and development fees for applying its gene-regulating platform technology to enhance its partners’ products.
Certain statements included in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors, including, but not limited to: the ability of the Company to consummate additional financings; the development of the Company’s gene technology; the approval of the Company’s patent applications; the successful implementation of the Company’s research and development programs and joint ventures; the success of the Company's license agreements; the acceptance by the market of the Company’s products; success of the Company’s preliminary studies and preclinical research; competition and the timing of projects and trends in future operating performance, the Company’s ability to meet its funding milestones under its financing transaction, the Company’s ability to continue to comply with the continued listing standards of the AMEX, as well as other factors expressed from time to time in the Company’s periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with the Company’s periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.